Choroidal Neovascularization Global Market Report 2025

The choroidal neovascularization market size has grown strongly in recent years. It will grow from $3.37 billion in 2024 to $3.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of sedentary lifestyle diseases, the rising incidence of age-related macular degeneration, a higher occurrence of retinal illnesses, a growing elderly population, escalating eye care costs, and expanding education and screening initiatives.

The choroidal neovascularization market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth during the forecast period can be attributed to factors such as increasing patient awareness, the growing adoption of optical coherence tomography angiography, rising demand for minimally invasive procedures, favorable reimbursement policies, and a growing geriatric population. Key trends in this period include the emergence of intravitreal anti-vascular endothelial growth factor (VEGF) therapies, new gene treatments, gene therapy approaches, the adoption of telemedicine, the development of combination therapies, and personalized treatment strategies.

The increasing prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the choroidal neovascularization (CNV) market in the future. AMD is an eye condition that gradually damages the macula, resulting in central vision loss, particularly among older adults. The rising prevalence of AMD is attributed to factors such as an aging population, increased life expectancy, lifestyle changes, genetic influences, and increased exposure to environmental risks. CNV plays a significant role in wet AMD, where abnormal blood vessel growth beneath the retina leads to vision deterioration. Advanced treatments such as anti-VEGF therapy are used to manage CNV, slow the progression of AMD, and help preserve central vision in affected individuals. For example, in September 2022, the National Institutes of Health projected that by 2040, AMD cases may reach 300 million, and by 2050, 5.4 million Americans could be affected. Therefore, the rising prevalence of AMD is driving the growth of the CNV market.

Leading companies in the CNV market are focusing on developing innovative treatments, such as photodynamic therapy (PDT), to provide eye care professionals with more precise and effective options that enhance patient outcomes and treatment delivery. PDT uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the approval of the ML6710i photodynamic laser by the U.S. Food and Drug Administration. This therapy is used in conjunction with Bausch + Lomb’s VISUDYNE therapy to treat CNV caused by AMD. The advanced, mobile ophthalmic laser offers a targeted approach to treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.

In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired the CIMERLI business from Coherus for $170 million. With this acquisition, Sandoz aims to expand its portfolio in the ophthalmic sector, strengthening its ability to offer innovative treatments for retinal diseases, such as AMD. Coherus BioSciences, a U.S.-based biopharmaceutical company, focuses on the research and development of treatments for diseases such as CNV.

Major players in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in choroidal neovascularization report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the choroidal neovascularization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage retinal tissues and lead to vision distortion or loss.

The main treatment options for choroidal neovascularization include anti-angiogenic therapy, laser photocoagulation, photodynamic therapy, verteporfin sodium, ranibizumab, bevacizumab, aflibercept, and pegaptanib sodium. Anti-angiogenic therapy works by inhibiting the formation of new blood vessels (angiogenesis), helping to prevent the growth of abnormal blood vessels. These treatments are commonly used for specific conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), myopic macular degeneration (MMD), and other related conditions. The administration route may vary, including intravitreal, subconjunctival, periocular, or oral methods. These therapies are primarily administered in hospitals, ophthalmology clinics, and ambulatory surgical centers.

The choroidal neovascularization market research report is one of a series of new reports that provides choroidal neovascularization market statistics, including the choroidal neovascularization industry global market size, regional shares, competitors with the choroidal neovascularization market share, detailed choroidal neovascularization market segments, market trends, and opportunities, and any further data you may need to thrive in the choroidal neovascularization industry. This choroidal neovascularization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The choroidal neovascularization market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The choroidal neovascularization market also includes sales of injections, therapy agents, and surgical & laser devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.